New Hope For Serious Infections
|
|
- Denis Wilkins
- 6 years ago
- Views:
Transcription
1 New Hope For Serious Infections
2 Forward-Looking Statements These slides and the accompanying oral presentation (the Presentation ) contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effectiveness, safety, long-acting nature, anticipated human dosing and other attributes of CD101 IV and its potential to treat infections, the incidence of fungal infections, and the effectiveness and treatment protocols for competitive therapies. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara s plans to develop and commercialize its product candidates; Cidara s ability to obtain additional financing; Cidara s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara s Form 10-Q most recently filed with the United States Securities and Exchange Commission (SEC), under the heading Risk Factors. All forward-looking statements contained in the Presentation speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
3 Cidara update: November 2015 CD101 IV Phase 1 SAD completed CD101 Topical Begin Phase 2 mid 2016 Cloudbreak Infectious disease immunotherapy
4 Cidara accomplishments since inception Series B: $42M Feb, 2015 Cidara formed Jan, 2014 Series A: $32M Jun, 2014 IPO: $77M Apr, Acquires CD101 portfolio May, 2014 Initiates CD101 Topical program Oct, 2014 Phase 1 SAD complete for CD101 IV Nov, 2015 Submits IND to FDA for CD101 IV Jun, 2015 FDA fast-track & QIDP for CD101 IV May, 2015
5 Cidara: an experienced team Jeff Stein, PhD CEO Dirk Thye, MD CMO Ken Bartizal, PhD CDO Paul Daruwala, RPh CCO Kevin Forrest, PhD COO Jim Balkovec, PhD SVP Research
6 Successful track record Antibacterial Antifungal Antiviral
7 Fungal infections: high mortality U.S. 12-Week Mortality per Annum by Species Candida 67,500 Aspergillus 22,500 Cryptococcus 4,500 97,000 deaths per year Rare fungi Fungi 2,500
8 CD101 Progress 4Q 2015 Program Indication Pre-Clin IND Enabling Phase 1 Phase 2 Phase 3 CD101 IV Candidemia/ Invasive Candidiasis CD101 Topical Acute and Recurrent VVC Projected 4Q 2016 Program Indication Pre-Clin IND Enabling Phase 1 Phase 2 Phase 3 CD101 IV Candidemia/ Invasive Candidiasis CD101 Topical Acute and Recurrent VVC
9 Cidara pipeline Program Indication Discovery Research/ In Vitro In Vivo IND Enabling Phase 1 Phase 2 CD101 IV Candidemia/ Invasive Candidiasis CD101 Topical Acute and Recurrent VVC Cloudbreak TM Platform Antifungal Cloudbreak Small and Large Molecule Programs Antibacterial Antiviral
10 CD101 A novel echinocandin antifungal in Phase I Structural modification yields superior chemical & biological properties Permanent charge and highly stable ring structure Prolongs PK: once weekly dosing Allows high exposures: treats less susceptible pathogens Eliminates toxic degradation products: improved safety & dose range Enables multiple formulations: systemic and topical ICAAC 2015
11 CD101 - potent against Candida and Aspergillus CD101, anidulafungin and caspofungin tested against a panel including azole & echinocandin-resistant strains Candida MIC 90 (µg/ml) Aspergillus MEC 90 (µg/ml) * albicans (n=100) glabrata (n=100) tropicalis (n=100) krusei (n=100) parapsilosis (n=100) fumigatus (n=20) terreus (n=19) niger (n=16) flavus (n=12) CD Anidulafungin < Caspofungin * CLSI methodology was employed for MIC/MEC determination, MECs vs Aspergillus were determined for CD101, anidulafungin and caspofungin. ICAAC 2014 & 2015
12 CD101 IV: superior efficacy at equivalent doses CFU in Kidneys of Mice 24 Hours after Infection with C. albicans and treatment with Anidulafungin or CD101 IV DOSE 0.0 mg/kg 0.5 mg/kg* 1.5 mg/kg** Log 10 CFU/Kidneys 5 Anidulafungin 4 3 CD101 IV Untreated Control Cohort 2 Cohort 3 *Statistically Significant at p < **Statistically Significant at p < 0.05
13 Phase 1 single ascending dose study design Number of Subjects by Dose DOSE 50mg 100mg 200mg 400mg TOTALS CD101 IV Placebo o Objective: Safety, tolerability and pharmacokinetics 32 Safety assessments included adverse events, ECGs, hematology, chemistry labs, urinalysis, vital signs, physical exam Subjects followed for 21 days after dosing
14 Phase 1 single ascending dose results Adverse Events by Dose DOSE 50mg 100mg 200mg 400mg Placebo Number of AEs Subjects w/ AEs 3 of 6 0 of 6 3 of 6 1 of 6 5 of 8 More Placebo AE than in all CD101 IV combined No serious AE No severe AE No dose-response in AE No withdrawals due to AE No vital sign, physical exam or ECG abnormalities No significant laboratory abnormalities (hematology, chemistry, LFTs)
15 Mean Plasma Conc (µg/ml) 1x weekly dosing achievable; high exposures CD101 IV Phase I PK Days 400mg 200mg
16 Mean Plasma Conc (µg/ml) 1x weekly dosing achievable; high exposures CD101 IV Phase I PK AUC ~2.5x higher C max 3x higher AUC ~1.6x higher Days Anidulafungin 100mg x 7 400mg x 1 200mg x 1
17 CD101 IV: streamlined development plan IND I II III Phase I Phase 2 Phase 3 PK and safety in healthy volunteers Double-blind vs. echinocandin in candidemia Non-inferiority vs. echinocandin in candidemia + High unmet need Broader initial label claim: invasive candidiasis
18 Systemic fungal infection market U.S. Days of Therapy (Millions) Inpatient M Inpatients Discharge 4.5 ~40% of inpatients on antifungals are discharged on antifungals outpatient Prophylaxis* 1.5 High risk for invasive fungal infection days of therapy per patient Global sales of the systemic antifungal market are ~$4B *High risk populations: Acute leukemia, Allo HSCT, SOT
19 Factors that favor CD101 IV 70% US % of non-albicans Candida International Epidemiology Guidelines Epidemiology International Guidelines 60% 2011 Pharmacoeconomics 50% 40% 2006 Converging factors increasing prevalence of non-albicans Candida 30% M. Pfaller. Mycoses, 2014, 57,
20 Factors converge to favor CD101 IV Epidemiology International Guidelines Pharmacoeconomics Superior efficacy of echinocandins vs azoles Rise in azole resistant pathogens Echinocandins recommended as first line therapy in candidemia Guidelines shifting to favor echinocandins Source: ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients; European Expert Opinion on the Management of Invasive Candidiasis in Adults
21 Cost saving opportunities in multiple settings US Cost Hospital Stay* US Cost Outpatient $10,616 Epidemiology International Guidelines Pharmacoeconomics $4,550 $7,583 $3,863 $6,702 3 Days General Ward 5 Days General Ward 7 Days General Ward 7 Days Micafungin OPAT 14 Days Micafungin OPAT KOLs estimate that 5-30% of patients on an echinocandin can be discharged 3-7 days early Assumptions: General ward cost per day - $1,516 OPAT: Micafungin cost per day (WAC) - $187, Cost of PICC placement - $1,024, Per diem OPAT costs - $219
22 The differentiating value of a weekly echinocandin INPATIENT POST DISCHARGE PROPHYLAXIS TARGET Stable, eligible for early discharge; removal of central line; longer term Tx Echinocandin continuation; azole challenged; nonalbicans Azole challenged: high risk acute leukemia, allo HSCT, SOT VALUE Reduce cost and improve care Improve outcomes vs azoles, decrease OPAT costs Reduce deadly infections Echinocandins ~20% of TOTAL DOT* <5% of DOT <5% of DOT CD101 Potential Million DOT* *Days of Therapy
23 Cloudbreak: a transformational technology Cloudbreak Physically connects the immune system with the pathogen Primes the immune system Vaccine Targets the pathogen Therapeutic The strengths of both systems
24 Cloudbreak concept and compound design Microbe TM EM Cell MICROBE TARGETING MOIETY EFFECTOR MOIETY HUMAN CELL Fungi Echiniocandin fmlf Neutrophil Fungal Hyphae Cidara Compound Neutrophils
25 Ex-vivo experimental design Microfluidic Schematic Actual microfluidics chamber Conidia Loading Neutrophil Input Well
26 Ex-vivo proof of concept for Cloudbreak No drug 1 nm C-001 (1/70 th MEC) ICAAC 2015 Bifunctional Small Molecule Immunotherapy. C-001 and C-016 Attract Neutrophils (PMNs) to Inhibit Aspergillus fumigatus (Af) Growth in Microfluidic Chambers, D. Irimia, et al.
27 Cloudbreak platform expansion Small Molecule Large Molecule Microbe TM EM Cell Microbe TM TM EM EM Cell TARGETING MOIETY EFFECTOR MOIETY TARGETING MOIETY EFFECTOR MOIETY Approved anti-microbial Small molecule & peptide-based immune engagers Antibody that binds cell-surface antigen Antibody that engages immune system INNATE IMMUNE SYSTEM ADAPTIVE IMMUNE SYSTEM
28 A450 nm Large Molecule Cloudbreak Microbe TM TM EM EM Cell Selected Immune Cells 1.5 Immune Cell Activation 1.0 Cells only TM TM-EM TM (-Antigen) TM(+Antigen) TM-EM(-Antigen) TM-EM(+Antigen) Microbe TM EM TM EM Cell Microbe TM EM TM EM Cell Microbe TM EM TM EM Cell
29 Cloudbreak Platform Expansion Anti-Bacterial Anti-Viral Indwelling Hardware Influenza
30 Upcoming Milestones Program Next Milestone Expected Timing CD101 IV Phase 1 MAD data Phase 2 Start Early H 2016 CD101 Topical Phase 2 start Mid 2016 Cloudbreak Platform Development candidate 2016
31 New Hope For Serious Infections
ESCMID Online Lecture Library. by author
Eric DANNAOUI ESCMID Postgraduate Education Course 20-22 June 2013, Sibiu Antifungal susceptibility testing and detection of resistance: principles and practices Unité de Parasitologie-Mycologie, Laboratoire
More informationECCMID SCY-078 Scientific Data Presentation Conference Call
A New Path for Antifungal Treatments ECCMID SCY-078 Scientific Data Presentation Conference Call April 25, 2017 4:05pm ET Forward-Looking Statements Certain statements regarding SCYNEXIS, Inc. (the Company
More informationCORPORATE PRESENTATION
A New Path for Antifungal Treatments Overview of SCY-078 -- First Representative of a Novel Oral/IV Triterpenoid Antifungal Family CORPORATE PRESENTATION September 2017 Forward-Looking Statements Certain
More informationAntifungal PK/PD Made Simple. David Andes, MD University of Wisconsin
Antifungal PK/PD Made Simple David Andes, MD University of Wisconsin PK/PD Concept Serum Drug Concentration Peak:MIC AUC:MIC Ratio Time Above MIC MIC Time Hypothesis and Concept There is an optimal drug
More informationCase. Case. Case. Case. Reference lab AST. Nelesh Govender, NICD 2013/03/08. Candida species: Antifungal susceptibility testing in 2013
Nelesh Govender, NICD 13/3/8 se ndida species: Antifungal susceptibility testing in 13 Nelesh Govender National Institute for Communicable Diseases and University of the Witwatersrand, Johannesburg Elderly
More informationSamatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection
Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection Douglas Mayers, MD December 11, 2013 1 Idenix: Advancing All-Oral, Pan-Genotypic Combination
More informationAnnual General Meeting KPMG Level 36, 727 Collins St Melbourne Tuesday 21 November am
Annual General Meeting 2017 KPMG Level 36, 727 Collins St Melbourne Tuesday 21 November 2017 11.00am Forward looking statements Certain statements in this presentation relate to the future, including forward
More informationAssembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015
Assembly Biosciences Jefferies 2015 Microbiome Summit December 16, 2015 Forward-Looking Statements This presentation contains forward-looking statements regarding future events. Forward-looking statements
More informationDr. Rukumani Devi Velayuthan Mycology Unit Co-ordinator PPUM
Antifungal sensitivity testing using VITEK 2 Dr. Rukumani Devi Velayuthan Mycology Unit Co-ordinator PPUM VITEK 2 Systems The VITEK 2 System is intended for the automated identification and susceptibility
More informationMomenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference
Momenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation contains forward-looking statements about our financial outlook,
More informationAdvancing New Treatments for DMD and C. difficile Infection
Advancing New Treatments for DMD and C. difficile Infection 34 th Annual Canaccord Genuity Growth Conference August 13, 2014 Legal Disclaimer FORWARD-LOOKING STATEMENTS This Document contains forward-looking
More informationPassive vaccination as a global strategy for preventing RSV disease in infants. Filip Dubovsky MD MPH FAAP MedImmune March 2016
Passive vaccination as a global strategy for preventing RSV disease in infants Filip Dubovsky MD MPH FAAP MedImmune March 2016 Outline for Presentation Rationale for passive immunization for RSV prophylaxis
More informationEmpfindlichkeitstestung bei Pilzen Neuigkeiten? Bericht aus einem EUCAST AFST (yeasts and moulds) Netzwerk-Laboratorium
Empfindlichkeitstestung bei Pilzen Neuigkeiten? Bericht aus einem EUCAST AFST (yeasts and moulds) Netzwerk-Laboratorium EUCAST reloaded 6.0 Follow-up Workshop 23.03.2017 Cornelia Lass-Flörl Division of
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationSYMBIOTIC HEALTH. Targeted GI Delivery of Orally Administered Cells and Proteins for Microbiome-Based Therapeutics
SYMBIOTIC HEALTH Targeted GI Delivery of Orally Administered Cells and Proteins for Microbiome-Based Therapeutics Contact: Gerard Honig PhD, Director ghonig@symbioticbio.com Overview Biotechnology startup
More information8. Clinical Trial Assessment Phase II
8. Clinical Trial Assessment Phase II Junko Sato, PhD Office of New Drug I, PMDA Disclaimer: The information within this presentation is based on the presenter s expertise and experience, and represents
More informationPassive Immunization Trials to Inform Vaccine Design
Passive Immunization Trials to Inform Vaccine Design Points for Consideration from deliberations held at the August 8, 2014 workshop Contents I. Introduction... 2 II. Types of trials... 2 1. Therapeutic
More informationCorporate Presentation. April 2016
Corporate Presentation April 2016 1 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationCorporate Presentation. March 2018
Corporate Presentation March 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation
More informationDelivering on the Promise of RNA- Based Therapeu;cs
Delivering on the Promise of RNA- Based Therapeu;cs Parent Project Muscular Dystrophy Webinar June 20, 2011 Forward- Looking Statements This presenta,on includes forward- looking statements, including
More informationPPTA Regulatory Workshop June 13, 2016
PPTA Regulatory Workshop June 13, 2016 DOROTY SCOTT Dr. Dorothy Scott is the Branch Chief for the Laboratory of Plasma Derivatives, in the Office of Blood Research and Review, CBER. Her group is responsible
More informationAlle Echinocandine sind gleich?
Alle Echinocandine sind gleich? Giftiger Donnerstag Hospital Velden, 1.06.2017 Cornelia Lass-Flörl Division of Hygiene and Medical Microbiology Innsbruck Medical University Indications Caspofungin - Candicas
More informationuniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B
uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B -- Second-dose Cohort Demonstrates Dose Response with All Patients
More informationINTERIM RESULTS AS OF MARCH 31, 2017
INTERIM RESULTS AS OF MARCH 31, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationOPT-302: a VEGF-C/VEGF-D Trap for wet AMD
OPT-302: a VEGF-C/VEGF-D Trap for wet AMD Ophthalmology Innovation Summit, Nov 12 2015 Circadian Technologies (ASX:CIR, OTCQX:CKDXY) Megan Baldwin PhD, CEO & MD megan.baldwin@opthea.com 2 Disclaimer Investment
More informationTogether, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days
Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting Together, all nine participants
More informationPreliminary Evaluation of a Semisolid Agar Antifungal Susceptibility Test for Yeasts and Molds
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2000, p. 537 541 Vol. 38, No. 2 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Preliminary Evaluation of a Semisolid
More informationShionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S ), a Siderophore Cephalosporin
Shionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S-649266), a Siderophore Cephalosporin Osaka, Japan, April 22, 2017 - Shionogi & Co., Ltd. today announced
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationExon Skipping. Wendy Erler Patient Advocacy Wave Life Sciences
Exon Skipping Wendy Erler Patient Advocacy Wave Life Sciences Forward Looking Statements This document contains forward-looking statements. All statements other than statements of historical facts contained
More informationSecond Quarter 2017 Financial Results. August 8, 2017
Second Quarter 2017 Financial Results August 8, 2017 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Sr. Manager, Investor Relations Business Highlights & 2017 Key Milestones
More information6/28/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics
Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical
More informationCelerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept. San Francisco, CA Tue 8 th, Apr 2014
Celerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept San Francisco, CA Tue 8 th, Apr 2014 Mind the Gap: Elements of a Bridging Strategy J. Fred Pritchard, Ph.D. Vice President,
More informationWelcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications
Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications 1 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning
More information10/2/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics
Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical
More informationRegulation of Microbiota- Based Products
Regulation of Microbiota- Based Products LCDR Matthew Steele, PhD Team Leader, Regulatory Review Branch 1 Division of Vaccines and Related Products Applications CBER/OVRR My presentation is an informal
More informationSIOPI MARIA, M.Sc. Clinical Chemistry
Personal information Date of birth: 20/09/1984 Place of birth: Athens, Greece Work address: Clinical Microbiology Laboratory, Attikon University General Hospital, 1 Rimini Str., Haidari, Athens 124 62,
More informationChallenges in Antimicrobial Clinical Development. Axel Dalhoff & Heino Staß Institut für Klinische Pharmakologie Bayer AG, Wuppertal, D
Challenges in Antimicrobial Clinical Development Axel Dalhoff & Heino Staß Institut für Klinische Pharmakologie Bayer AG, Wuppertal, D New antibacterial agents approved in the United States 1983-2002 No.
More informationVolunteering for Clinical Trials
Volunteering for Clinical Trials Volunteering for Clinical Trials When considering volunteering for a clinical trial, it is important to make an informed decision. Below are answers to frequently asked
More informationDeveloping innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO
Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO (lglass@neurenpharma.com) Neuren Pharmaceuticals Created to commercialize University of
More informationDesigning Safe and Efficient Phase I Studies to Expedite Clinical Development
Designing Safe and Efficient Phase I Studies to Expedite Clinical Development Mario Tanguay, B.Pharm, Ph.D. Vice President, Scientific & Regulatory Affairs, Anapharm Guest Professor, Faculty of Pharmacy,
More informationCarbavance. TANGO-1 phase III trial results. (meropenem-vaborbactam) Conference call 27 th June 2016
Carbavance (meropenem-vaborbactam) TANGO-1 phase III trial results Conference call 27 th June 2016 Legal notices Forward looking statements Statements contained in this presentation about The Medicines
More informationRegulatory Pathways for Rare Diseases
Regulatory Pathways for Rare Diseases Celia M. Witten, Ph.D., M.D. Deputy Director, FDA Center for Biologics Evaluation and Research Emerging Technologies for Rare Diseases: Clinical and Regulatory Case
More informationThe science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway
The science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway Speaker credentials Roy H. Larsen, PhD >25 years of experience in research on targeted radionuclide therapy
More informationCreating Highly Efficacious ADCs for Low-Expression Targets While Improving Therapeutic Index TIM LOWINGER, PHD
Creating Highly Efficacious ADCs for Low-Expression Targets While Improving Therapeutic Index TIM LOWINGER, PHD CSO Mersana Therapeutics VC-backed Biotech in Cambridge, MA Investors: NEA, Pfizer, Fidelity,
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationVulvovaginal Candidiasis due to non albicans Candida: its species distribution and antifungal susceptibility profile
ISSN: 2319-7706 Volume 2 Number 12 (2013) pp. 323-328 http://www.ijcmas.com Original Research Article Vulvovaginal Candidiasis due to non albicans Candida: its species distribution and antifungal susceptibility
More informationCiti s 2017 Global Healthcare Conference 6~7 December 2017, New York
Citi s 2017 Global Healthcare Conference 6~7 December 2017, New York Safe Harbor Statement forward-looking statements. These forward-looking statements may be identified by words sthis presentation contains
More informationFDA Oversight of Gene Therapy
FDA Oversight of Gene Therapy Celia M. Witten, Ph.D., M.D. Deputy Director, FDA CBER Rare Disease and Orphan Products Breakthrough Summit NORD October 17, 2016 Hyatt Regency Crystal City Crystal City,
More informationThe Drug Development Process and Design of Clinical Trials
The Drug Development Process and Design of Clinical Trials Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 Clinical Trial Design Guidance Clinical Trial:
More informationIntroduction. This booklet also highlights ways to minimise the potential risks associated with micafungin use.
1 2 Introduction This booklet for prescribers and nurses provides practical guidance on the safe use and administration of micafungin, an echinocandin antifungal drug. This booklet also highlights ways
More informationMark Crowther, MD, MSc, FRCPC. Co-authors. Professor of Medicine, McMaster University, Canada
Reversal of Enoxaparin-Induced Anticoagulation in Healthy Subjects by Andexanet Alfa (PRT064445), An Antidote for Direct and Indirect fxa Inhibitors A Phase 2 Randomized, Double-Blind, Placebo Controlled
More informationInjectable modified release products
Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) Injectable modified release products Dr Sotiris Michaleas, National Expert for the
More informationPharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.
Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationPK/PD als Instrument zur Steuerung der klinischen Entwicklung von Antibiotika
PK/PD als Instrument zur Steuerung der klinischen Entwicklung von Antibiotika Heino Staß Institut für Klinische Pharmakologie Bayer HealthCare AG, Wuppertal, D Role of Clinical Pharmacology in the Development
More informationGenMark Diagnostics TRANSFORMING MULTIPLEX MOLECULAR TESTING. J.P. Morgan Healthcare Conference 2018
GenMark Diagnostics TRANSFORMING MULTIPLEX MOLECULAR TESTING J.P. Morgan Healthcare Conference 2018 1 Forward-Looking Statements This presentation contains forward-looking statements about GenMark Diagnostics,
More informationEarly Phase Education WHITEPAPER. Three major items to consider when moving from preclinical to clinical development
Early Phase Education WHITEPAPER Three major items to consider when moving from preclinical to clinical development Three major items to consider when moving from preclinical to clinical development Dr.
More informationIdentification of Candida inconspicua clinical isolates and testing of fluconazole, amphotericin B, flucytosine and caspofungin susceptibility
Identification of Candida inconspicua clinical isolates and testing of fluconazole, amphotericin B, flucytosine and caspofungin susceptibility Ph.D. theses László Majoros Department of Medical Microbiology,
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationSingapore nanotechnology combats fatal brain infections
P ublic release date: 28-Jun-2009 Contact: Cathy Yarbrough sciencematter@yahoo.com 858-243-1814 Agency for Science, Technology and Research (A*STAR), Singapore Singapore nanotechnology combats fatal brain
More informationPfizer Program in DMD. Beth Belluscio, MD-Ph.D. Pfizer Rare Disease September 9, 2017
Pfizer Program in DMD Beth Belluscio, MD-Ph.D. Pfizer Rare Disease September 9, 2017 Myostatin Inhibitor for the Potential Treatment of Duchenne Muscular Dystrophy Disclaimer This presentation includes
More informationWhen to Stop Dose Escalation: MTD, MLD or?
When to Stop Dose Escalation: MTD, MLD or? Henri CAPLAIN First Joint Annual Meeting, AGAH Club Phase 1 STRASBOURG, France 1 So called MTD STOP FIM No MTD? 2 WHY WE NEED TO REACH THE MAXIMUM TOLERATED DOSE
More informationAlle Echinocandine sind gleich?
Alle Echinocandine sind gleich? Giftiger Donnerstag Hospital Innsbruck, 14.09.2017 Cornelia Lass-Flörl Division of Hygiene and Medical Microbiology Innsbruck Medical University Indications Caspofungin
More informationThe Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes
More informationReceived 4 May 2011/Returned for modification 20 July 2011/Accepted 23 July 2011
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2011, p. 4880 4887 Vol. 55, No. 10 0066-4804/11/$12.00 doi:10.1128/aac.00621-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Pharmacodynamics
More informationectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA
ectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationCOMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 16 June 2005 EMEA/CHMP/94526/2005 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) ANNEX GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS
More informationDeveloping T cell vaccines for HSV-2 Infection
Developing T cell vaccines for HSV-2 Infection Jessica Baker Flechtner, PhD World Vaccine Congress 24-26 March, 2014 Deep Pipeline of T Cell-Enabled Vaccine Candidates Discovery Pre-clinical Phase 1 Phase
More informationProfibrinolytic diabody targeting PAI-1 and TAFI for treatment of acute thrombotic disorders
ProFiDIΛ Profibrinolytic diabody targeting PAI-1 and TAFI for treatment of acute thrombotic disorders THROMBOLYSIS WITH IMPROVED SAFETY A valorisation project of Unmet Medical Need = Safe Thrombolysis
More informationscr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL UPDATE ZACKS ESTIMATES
Small-Cap Research February 9, 2016 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Matinas BioPharma Holdings, Inc. MTNB: Patient Enrollment
More informationDUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM
DUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM Dana R. Martin, PharmD Sarepta Therapeutics PPMD ANNUAL CONNECT CONFERENCE ORLANDO, FLORIDA JUNE 27, 2016 FORWARD LOOKING STATEMENTS This presentation,
More informationA Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
1 von 5 10.12.2013 10:33 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: MOR202C101 Previous Study Return to List Next Study A Phase I/IIa Study of Human Anti-CD38 Antibody
More informationTavaborole demonstrates solid efficacy and safety in Phase III trials
Anacor s Drug Tavaborole Should Receive FDA Approval On May 29, 2013, Anacor Pharmaceuticals (ANAC) announced successful completion of pre- NDA (New Drug Approval) communication with the U.S. Food and
More informationAnti- THrombosis with Enoxaparin in intubated Adolescents
Anti- THrombosis with Enoxaparin in intubated Adolescents E. Vincent S. Faustino, MD, MHS October 2017 NHLBI submission S L I D E 0 Research question, central hypothesis and primary aim Research Question
More informationUnderstanding clinical research trials
Understanding clinical research trials Dr. Isabelle Fleury Medical Hemato-oncologist Hôpital Maisonneuve-Rosemont CIUSSS de l Est-de-l Île-de-Montréal Goals of this presentation Better understand clinical
More informationRapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products
RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products Kevin Kane, Scientific Director, BCP 7 th Annual Global Drug Delivery & Formulation Summit 28 th August
More informationOncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory Challenges
The content of this presentation reflects the opinion of the speaker and does not necessarily represent the official position of CDER Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory
More informationDivision of Dockets Management (HFA 305) U.S. Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852
May 24, 2012 Division of Dockets Management (HFA 305) U.S. Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 Re: Comments on Docket #FDA- 2012 D 0148; Draft Guidance for Industry
More informationSummary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015
Pediatric-Specific Provisions Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Requires the NIH to complete a strategic plan, and in the
More informationLong-Term Follow-Up in Gene Transfer Clinical Research
Long-Term Follow-Up in Gene Transfer Clinical Research Jan P. Vleck, MD CIP Institutional Biosafety Committee Services A Division of WIRB www.ibcservicepoint.com ibcs@wirb.com What is LTFU? the collection
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
23 July 2015 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular
More informationExpanded Access to Investigational Imaging Drugs
Expanded Access to Investigational Imaging Drugs Phillip B. Davis, MD FDA/CDER/ODEIV/DMIP 6/09/2016 1 Overview Expanded Access (EA) Defined Requirements for all EA authorizations Types of EA Individual
More information+ + + MALARIA HIV/AIDS TUBERCULOSIS LEISHMANIASIS CHAGAS DISEASE DENGUE EBOLA ZIKA
At the Center for Infectious Disease Research, we use systems biology approaches and cutting-edge technologies to accelerate the development of life-saving drugs, diagnostics and treatments for the world
More informationDefining Clinical Benefit in Clinical Trials: FDA Perspective
Defining Clinical Benefit in Clinical Trials: FDA Perspective Jessica J. Lee, MD, MMSc Medical Team Leader Division of Gastroenterology and Inborn Errors Products Center for Drug Evaluation and Research
More informationPost-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER CSRC/DIA Think Tank June 3, 2016 Oanh Dang, PharmD, BCPS Division of Pharmacovigilance Safety Evaluator Office of Surveillance and
More informationVerification of Disk Diffusion Tests
Verification of Disk Diffusion Tests Objectives 1. Describe disk diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification of
More informationDRUG DEVELOPMENT TARGET PRODUCT PROFILE
DRUG DEVELOPMENT TARGET PRODUCT PROFILE Template This template provides suggested considerations that may assist biopharmaceutical companies in their decisions as to whether to proceed with a drug development
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationRecommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation
2 March 2010 EMA/COMP/15893/2009 Final Committee for Orphan Medicinal Products (COMP) Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for
More informationFebruary 28, Churchill Place Canary Wharf London E14 5EU United Kingdom
February 28, 2017 Submission of comments on 'Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products' (EMEA/CHMP/SWP/28367/07
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
1 2 3 15 November 2012 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous
More informationFDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D.
Speaker Comparing The Effectiveness Of New Drugs: Should The FDA Be Asking 'Does It Work' Or 'Does It Work Better'? Vicki L. Seyfert-Margolis, PhD Senior Advisor, Science Innovation and Policy U.S. Food
More informationOptimisation de votre programme de développement
Optimisation de votre programme de développement Cedric Lamy, PhD. Cedric.lamy@crl.com Charles River Overview 65-year history: Founded in 1946, publicly traded (NYSE:CRL) Investment in skilled staff: ~7,500
More informationFood and Drug Administration (FDA) 101
Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the
More information